Memorial Sloan Kettering Cancer Center

Perioperative nivolumab demonstrated no negative impact on health-related quality of life while reducing the risk of deterioration compared to placebo in patients with stage III N2 or non-N2 non-small cell lung cancer.

BostonGene published a study in Cell Reports Medicine introducing the largest harmonized transcriptomic and clinical dataset in kidney cancer, analyzing over 3,600 patient samples.

Abdera Therapeutics presented initial Phase 1 clinical data for ABD-147, a novel DLL3-targeting radiopharmaceutical delivering Actinium-225 to small cell lung cancer tumors.

Tempus AI has acquired Paige, an AI company specializing in digital pathology with FDA-cleared cancer detection applications and nearly 7 million digitized pathology slides.

The phase 3 ARCHER trial (NRG-GU015) is now enrolling 486 patients to compare ultra-hypofractionated stereotactic body radiation therapy (5 treatments) versus standard hypofractionated radiotherapy (20 treatments) for muscle invasive bladder cancer.

A modified CD40 agonist antibody called 2141-V11 demonstrated remarkable efficacy in a phase 1 clinical trial, with six of 12 patients experiencing significant tumor reduction and two achieving complete remission.

Mabwell has dosed the first patient in a US clinical study of Bulumtatug Fuvedotin (BFv), a novel nectin-4-targeting ADC, at Memorial Sloan Kettering Cancer Center for triple-negative breast cancer patients previously treated with ADCs.

The Independent Data Monitoring Committee completed a pre-specified analysis of SELLAS' Phase 3 REGAL trial and recommended continuing the study without modification, finding no safety concerns.

A multi-institutional study found that 42% of ovarian cancer patients who achieved clinical remission after first-line therapy still harbored minimal residual disease (MRD) detectable through second-look laparoscopy.

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.